Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 14/20 | 0.65 |
| ▸ | LPAR2 | Q9HBW0 | 8/20 | 0.65 |
| ▸ | LPAR1 | Q92633 | 6/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
| ▸ | CDC25A | P30304 | 1/20 | 0.43 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.43 |
| ▸ | AKT1 | P31749 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5850881 | 0.98 | LPAR3 (0.69) | LPAR3LPAR2LPAR1CYP3A4LPAR5 | |
| SCHEMBL9463317 | 0.98 | LPAR3 (0.69) | LPAR3LPAR2LPAR1CYP3A4LPAR5 | |
| SCHEMBL57561 | 0.93 | — | — | |
| SCHEMBL5880403 | 0.85 | LPAR3 (0.50) | LPAR3LPAR2LPAR1CYP3A4LPAR5 | |
| SCHEMBL7278371 | 0.83 | — | — | |
| SCHEMBL9422627 | 0.83 | — | — | |
| SCHEMBL6629300 | 0.82 | LPAR3 (0.65) | LPAR3LPAR2LPAR1CYP3A4LPAR5 | |
| SCHEMBL251880 | 0.81 | LPAR3 (0.58) | LPAR3LPAR2LPAR1CYP3A4LPAR5 | |
| SCHEMBL497151 | 0.81 | LPAR3 (0.71) | LPAR3LPAR2LPAR1CYP3A4LPAR5 | |
| SCHEMBL56778 | 0.81 | LPAR3 (0.95) | LPAR3LPAR2LPAR1CYP3A4LPAR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030083490-A1 | Solution phase synthesis of oligonucleotides | AVECIA LIMITED | 2003-05-01 | — | — | US | claimed |
| EP-1003758-B1 | SOLUTION PHASE SYNTHESIS OF OLIGONUCLEOTIDES | AVECIA LTD (GB) | 2003-04-09 | — | — | EP | claimed |
| JP-2001515086-A | — | — | 2001-09-18 | — | — | JP | claimed |
| EP-1003758-A2 | SOLUTION PHASE SYNTHESIS OF OLIGONUCLEOTIDES | Avecia Limited (GB) | 2000-05-31 | — | — | EP | claimed |
| WO-1999009041-A2 | SOLUTION PHASE SYNTHESIS OF OLIGONUCLEOTIDES | AVECIA LIMITED (GB) | 1999-02-25 | — | — | WO | claimed |
| EP-0370317-B1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED 2-CHLOROPYRIDINES | BAYER AG (DE) | 1993-06-02 | — | — | EP | claimed |
| US-5010201-A | Process for the preparation of substituted 2-chloropyridines | BAYER AKTIENGESELLSCHAFT (DE) | 1991-04-23 | — | — | US | claimed |
| JP-60097987-A | — | — | None | — | — | JP | disclosed |
| WO-2024132849-A1 | PPS COMPOSITION, PROCESS FOR PREPARATION, PROCESS FOR PRODUCING AN ARTICLE, AND ARTICLE MADE OF THE COMPOSITION | DSM IP ASSETS B.V. (NL) | 2024-06-27 | — | — | WO | disclosed |
| US-11925658-B2 | Phosphoramidate derivatives of 5-fluoro-2′—deoxyuridine for use in the treatment of cancer | NuCana plc (GB) | 2024-03-12 | — | — | US | disclosed |
| US-20230165886-A1 | PHOSPHORAMIDATE DERIVATIVES OF 5 - FLUORO - 2' - DEOXYURIDINE FOR USE IN THE TREATMENT OF CANCER | NuCana plc (GB) | 2023-06-01 | — | — | US | disclosed |
| US-11559542-B2 | Phosphoramidate derivatives of 5-fluoro-2′-deoxyuridine for use in the treatment of cancer | NuCana plc (GB) | 2023-01-24 | — | — | US | disclosed |
| EP-4023299-A1 | PHOSPHORAMIDATE DERIVATIVES OF 5-FLUORO-2'-DEOXYURIDINE FOR USE IN THE TREATMENT OF CANCER | Nucana PLC (GB) | 2022-07-06 | — | — | EP | disclosed |
| US-5637680-A | Process for the preparation of etoposide phosphate and intermediate thereof | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1997-06-10 | — | — | US | disclosed |
| US-5606039-A | Etoposide phosphate and preparative intermediates | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1997-02-25 | — | — | US | disclosed |
| EP-0567089-B1 | Process for the preparation of etoposide phosphate and intermediates thereof | NIPPON KAYAKU KK (JP) | 1995-10-25 | — | — | EP | disclosed |
| EP-0567089-A1 | Process for the preparation of etoposide phosphate and intermediates thereof | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1993-10-27 | — | — | EP | disclosed |
| US-5010201-A | Process for the preparation of substituted 2-chloropyridines | BAYER AKTIENGESELLSCHAFT (DE) | 1991-04-23 | — | — | US | disclosed |
| JP-S6097987-A | PRODUCTION OF PHOSPHONIC ACID MONOESTER | NISSAN CHEM IND LTD | 1985-05-31 | — | — | JP | disclosed |
| US-4144290-A | Production of bromoaryl chlorophosphates | BAYER AKTIENGESELLSCHAFT (DE) | 1979-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230165886-A1 | PHOSPHORAMIDATE DERIVATIVES OF 5 - FLUORO - 2' - DEOXYURIDINE FOR USE IN THE TREATMENT OF CANCER | SLC29A2, SLC29A1, TYMP | LPAR3 4266/4885LPAR2 4040/4885LPAR1 4119/4885 |
| US-11559542-B2 | Phosphoramidate derivatives of 5-fluoro-2′-deoxyuridine for use in the treatment of cancer | SLC29A2, SLC29A1, TYMP | LPAR3 4262/4885LPAR2 4038/4885LPAR1 4126/4885 |
| US-20030083490-A1 | Solution phase synthesis of oligonucleotides | NUDT1, POLR2E, POLRMT | LPAR3 1903/4885LPAR2 2360/4885LPAR1 2362/4885 |
| US-11925658-B2 | Phosphoramidate derivatives of 5-fluoro-2′—deoxyuridine for use in the treatment of cancer | SLC29A2, SLC29A1, TYMP | LPAR3 4241/4885LPAR2 4013/4885LPAR1 4112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.